Reference source : WTO
Biocidal Products Regulation (BPR) Biocidal Products Active Substances Non-Approval Treated Articles Public Consultation
On 6 August 2026, the European Union notified the World Trade Organization (WTO) of a draft Commission Implementing Decision proposing the non-approval of three active substances for specific product types under the Biocidal Products Regulation (BPR) (Regulation (EU) No 528/2012). This follows the withdrawal of support for the affected active substance/product-type combinations by all participants in the review programme. Comments on the draft may be submitted until 5 October 2026.
Active Substance/Product-Type Combinations Affected
The draft Decision would not approve the following active substance/product-type combinations:
|
Active substance |
CAS No. |
Product type(s) |
|
Hydrogen peroxide |
7722-84-1 |
PT 12 |
|
Alkyl (C12-C14) dimethylbenzylammonium chloride (ADBAC (C12-C14)) |
85409-22-9 |
PT 22 |
|
Active bromine generated from sodium bromide by electrolysis |
– |
PT 11 and PT 12 |
These active substance/product-type combinations are included in the review programme for existing active substances under Commission Delegated Regulation (EU) No 1062/2014. According to the draft Decision, all participants withdrew, or were considered to have withdrawn, their support for these combinations.
For active bromine generated from sodium bromide by electrolysis (PT 11 and PT 12) and ADBAC (C12-C14) (PT 22), the European Chemicals Agency (ECHA) published an open invitation for other companies to take over the role of participant. However, no notifications were submitted within the required timeframe. For hydrogen peroxide (PT 12), the participant that had previously taken over the dossier also withdrew its support.
Regulatory Consequences
Consequently, the European Commission proposes not to approve these active substance/product-type combinations for use in biocidal products under the BPR.
If this proposal is adopted, biocidal products that rely on these approvals will no longer be eligible for authorisation for the affected product types. In addition, articles treated with or incorporating these active substances for the affected uses could no longer be placed on the EU market 180 days after the Decision takes effect.
The draft Decision is expected to be adopted in December 2026, enter into force 20 days after publication in the Official Journal of the European Union, and apply 12 months after adoption.
